1/16/2014 8:04:39 AM
Teva Pharmaceutical Industries Ltd. (TEVA:US) rose to a one-year high after the maker of generic medicines said it plans to return to a deal-making strategy that made it one of the most acquisitive drug companies of the past decade. Teva’s American depositary receipts jumped 6.7 percent to $44.21 at the close in New York yesterday, the highest since May 8, 2012. The drugmaker’s Israel-traded shares gained 7.2 percent to 154.20 shekels at the close today in Tel Aviv.
Help employers find you! Check out all the jobs and post your resume.
comments powered by